Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06720987 · ClinicalTrials.gov registry record · Phase 1

A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

A Phase 1 study of Solid Tumor Malignancies and CRC, Colorectal Cancer, sponsored by Kumquat Biosciences.

Recruiting
Registry status
Phase 1
Development phase
128
Enrollment target
9
Study locations

NCT06720987 is a Phase 1 study of Solid Tumor Malignancies and CRC, Colorectal Cancer that is actively recruiting participants, run by Kumquat Biosciences. The registered enrollment target is 128 participants, below the 184-participant average among 11 other Solid Tumor Malignancies trials with a reported enrollment target (30% lower). The trial reports 9 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06720987, a Phase 1 study of Solid Tumor Malignancies and CRC, Colorectal Cancer, is actively recruiting participants, sponsored by Kumquat Biosciences.

RECRUITING
Registry status
Phase 1
Development phase
128 participants
Enrollment target
9
Study locations

Study Summary

The goal of this clinical trial is to learn if KQB365 works to treat advanced solid tumor cancer in adults. It will also learn about the safety of KQB365. The main questions it aims to answer are: * What is the safe dose of KQB365 by itself or in combination with cetuximab? * Does KQB365 alone or in combination with cetuximab decrease the size of the tumor? * What happens to KQB365 in the body? Participants will: * Receive KQB365 infusion weekly alone or in combination with cetuximab * Visit the clinic about 9 times in the first 6 weeks, and then once every week after that.

Conditions Studied

Solid Tumor Malignancies CRC, Colorectal Cancer KRAS G12C Mutation KRAS G12S Mutation

Interventions

  • DRUG Cetuximab
  • DRUG KQB365

Study Locations (9)

Arizona

  • Mayo Clinic, Phoenix - Phoenix

Colorado

  • Sarah Cannon Cancer Institute at HealthONE - Denver

Florida

  • Mayo Clinic, Jacksonville - Jacksonville

Massachusetts

  • Dana Farber Cancer Institute - Boston

Michigan

  • START Midwest - Grand Rapids

Minnesota

  • Mayo Clinic, Rochester - Rochester

Ohio

  • Cleveland Clinic, Taussig Cancer Institute - Cleveland

Texas

  • NEXT Oncology - San Antonio

Trial Details

FieldValue
Enrollment Target 128 participants
Start Date 2025-02-04
Est. Completion 2030-06-30
Phase Phase 1

Sponsor

Kumquat Biosciences

6 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06720987

The ClinicalTrials.gov registry entry for NCT06720987 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 128 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 184-participant average among 11 other Solid Tumor Malignancies trials with a reported enrollment target (30% lower). The listed sponsor is Kumquat Biosciences, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Solid Tumor Malignancies appearing as the primary indexed condition, and to 2 interventions - of which Cetuximab is the first listed.

NCT06720987 reports 9 study locations spanning 9 distinct geographic areas - top geographies include Arizona, Colorado, Florida.

Frequently Asked Questions

What is clinical trial NCT06720987 about?

NCT06720987 is a clinical study titled "A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies". The goal of this clinical trial is to learn if KQB365 works to treat advanced solid tumor cancer in adults. It will also learn about the safety of KQB365. The main questions it aims to answer are: * What is the safe dose of KQB365 by itself or in combination with cetuximab? * Does KQB365 alone or i...

What is the current status of trial NCT06720987?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 128 participants. The study started on 2025-02-04. Estimated completion is 2030-06-30.

What conditions does trial NCT06720987 study?

This clinical trial studies the following conditions: Solid Tumor Malignancies, CRC, Colorectal Cancer, KRAS G12C Mutation, KRAS G12S Mutation.

What interventions are being tested in trial NCT06720987?

The interventions under investigation include: Cetuximab (DRUG), KQB365 (DRUG).

Who is sponsoring clinical trial NCT06720987?

This trial is sponsored by Kumquat Biosciences, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06720987 being conducted?

This trial has 9 study locations across Arizona, Colorado, Florida, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumor Malignancies

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Solid Tumor Malignancies

All registered trials for this condition

CRC, Colorectal Cancer

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.